IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial
Publication Date
11-15-2023
Presented At:
Annual Meeting. Society for Neuro-Oncology (SNO)
Content Type
Presentation
Publisher's Site:
Citation
Ozair, A., Alban, T., Grabowski, M., Otvos, B., Bayik, D., Bamashmos, A., Rayman, P., Diaz, M., Khosla, A., Bellur, S., McDermott, M., Reardon, D., Wen, P., Mohammadi, A., Peereboom, D., Lathia, J., & Ahluwalia, M. (2023). IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial. Neuro-Oncology, 25(Supplement_5), v149-v149. https://doi.org/10.1093/neuonc/noad179.0566